Semaglutide's most common side effects are mild-to-moderate GI issues like nausea, and while it increases gallstone risk, no unexpected safety problems have emerged from large-scale trials.
No unexpected safety signalsAcross the full SUSTAIN and PIONEER phase 3 trial programs plus cardiovascular outcome trials, semaglutide showed no safety issues beyond what's seen with other GLP-1 receptor agonists
What the researchers found
Semaglutide's safety profile shows mainly transient GI side effects and increased cholelithiasis risk, with no unexpected safety signals across SUSTAIN and PIONEER trials and favorable cardiovascular outcomes.
Why it matters
Semaglutide is one of the most prescribed diabetes and weight loss drugs. A thorough safety review helps doctors and patients make informed decisions about long-term use.
The numbers in context
GI effects: mild-moderate, transient; cholelithiasis increased; no proven pancreatic cancer; thyroid cancer inconclusive; rare hypoglycemia; DRP monitoring needed; CV outcomes beneficial
How the study worked
Comprehensive review of phase 3 registration trials (SUSTAIN and PIONEER programs), cardiovascular outcome trials, and emerging real-world evidence for both subcutaneous and oral semaglutide.
Who was studied
Review of SUSTAIN and PIONEER phase 3 trial programs and real-world evidence for subcutaneous and oral semaglutide in type 2 diabetes
What this study cannot tell us
Review of trial data with limited long-term follow-up for rare events like cancer. Real-world data is still accumulating. Some safety concerns (thyroid, pancreas) cannot be fully resolved with current evidence due to low event rates.
How to read the evidence
Rated strong because this review synthesizes data from multiple large phase 3 randomized controlled trials (SUSTAIN and PIONEER programs) plus cardiovascular outcome trials, representing the highest level of pre-approval evidence available for a drug.
When this study was published
Published in 2021, this review covers safety data available at the time of semaglutide's market establishment. Since then, additional real-world data and higher-dose weight-loss trials have further informed the safety picture, but the core findings remain relevant.
The bigger picture
With millions of people now taking semaglutide for diabetes and weight loss, understanding its safety profile is critical. This review, published when semaglutide was still relatively new, established the baseline safety picture that has largely held up — GI side effects are the main issue, serious events are rare, and cardiovascular outcomes are actually improved. The unresolved thyroid cancer question continues to generate research attention.
Questions still open
- Will longer follow-up eventually clarify the thyroid and pancreatic cancer questions that low event rates leave unanswered?
- Does the safety profile change meaningfully when semaglutide is used at higher doses for weight loss rather than diabetes?
- How does real-world safety data compare to the controlled trial environment?
Common questions
What are the most common side effects of semaglutide?
Does semaglutide cause thyroid cancer?
Read the original research
Safety of Semaglutide.
Frontiers in endocrinology, 12, 645563
Citation
Smits, Mark M; Van Raalte, Daniël H. (2021). Safety of Semaglutide.. Frontiers in endocrinology, 12, 645563. https://doi.org/10.3389/fendo.2021.645563